Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report.

A 56-year-old male patient was admitted due to a "rectal malignant tumor". He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short. The rash was treated with methylprednisolone + promethazine + calcium gluconate, and the neutropenia was treated by subcutaneous injection of the Recombinant Human Granulocyte Colony-Stimulating Factor Injection, the symptoms were relieved. Moreover, rashes and neutropenia are known common adverse reactions after intravenous administration of FOLFOX regimen. Based on the patient's symptoms and the timing of drug administration, a diagnosis of "rash and neutropenia due to the use of FOLFOX regimen" was made. Oxaliplatin and CF may also cause allergic reactions, including skin erythema and anaphylactic shock, etc. Once allergic reaction occurs, the fatality rate is higher than that of Penicillin. Therefore, sufficient attention should be paid to the patients reported in this paper who received FOLFOX regimen for multiple times and had multiple rashes and adverse reactions of neutropenia. Medical staff should closely monitored the adverse reactions and changes in vital signs of patients treated with this regimen during chemotherapy, and the chemotherapy regimen should be adjusted or terminated when necessary. The adverse reactions reported in this article deserve clinical attention.

Surfactant-free synthesis of hollow mesoporous carbon spheres and their encapsulated Au derivatives using biopolymeric chitosan.

To realize surfactant-free synthesis of biomass-derived hollow mesoporous carbon spheres and their derivatives, choice of synthetic methodology and carbon precursor is crucial. Herein, a brand-new hollow mesoporous carbon sphere (HMCS) is first synthesized from 8-quinolinol modified chitosan via an in situ stöber templating approach without surfactant followed by pyrolysis and alkali washing. The resultant HMCS is uniform, and shows a cavity size of 417 nm, a shell thickness of 5 nm, and a narrow mesopore size distribution centered at 3.9 nm. The HMCS is then upgraded by encapsulation of a single Au nanocrystal (NC) into the void of HMCS to form a yolk-shell architecture, YS-Au@HMCS. Its cavity size and shell thickness are decreased to 187 and 3 nm, while the mesopore size is increased to 4.3 nm, the surface area (215 m2 g-1) and mesoporosity (74.7%) are triple and twice that of HMCS, respectively, just by halving the delay time of carbon source addition. Owing to the unique hollow interiors and mesopores, as well as their synergism with the encapsulated Au NCs, the elaborately fabricated YS-Au@HMCS exhibits appealing catalytic performances towards the deposal of sewage. It delivers a large activity factor of 34.32, 13.29 and 0.05 s-1 g-1 in the reduction of 4-nitrophenol and methylene blue using sodium borohydride, and in the photodegradation of methylene blue under visible light irradiation, respectively. These advances shed new light on the synthesis of hollow mesoporous carbon spheres and the designed synthesis of functional carbon materials with versatile applications.

[Risk factors for congenital anal atresia].

OBJECTIVE: To investigate the risk factors for the development of congenital anal atresia in neonates. METHODS: A total of 70 neonates who were admitted to 17 hospitals in Foshan, China from January 2011 to December 2014 were enrolled as case group, and another 70 neonates who were hospitalized during the same period and had no anal atresia or other severe deformities were enrolled as control group. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for the development of congenital anal atresia. RESULTS: The univariate analysis revealed that the age of mothers, presence of oral administration of folic acid, infection during early pregnancy, and polyhydramnios, and sex of neonates showed significant differences between the case and control groups (P<0.05). The multivariate logistic regression analysis revealed that infection during early pregnancy (OR=18.776) and male neonates (OR=9.304) were risk factors for congenital anal atresia, and oral administration of folic acid during early pregnancy was the protective factor (OR=0.086). CONCLUSIONS: Infection during early pregnancy is the risk factor for congenital anal atresia, and male neonates are more likely to develop congenital anal atresia than female neonates. Supplementation of folic acid during early pregnancy can reduce the risk of congenital anal atresia.